Detection of Human Papillomavirus Genotypes Among High-Risk Women: A Comparison of Hybrid Capture and Linear Array Tests

Monsonégo, Joseph; Pollini, G; Evrard, Marie José; Sednaoui, Patrice; Monfort, Laura; Zerat, Laurent; Syrjänen, Karí

doi:10.1097/olq.0b013e318164e567

Cited by 26 publications

(30 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Specifically, 8 of 15 specimens that were HR HPV negative and LR HPV positive by hc2 were subsequently found to have HR genotypes by LA. This is not surprising, as previous studies comparing hc2 and LA have reported a slightly higher sensitivity, but lower specificity, with the LA (11,14,20,28).…”

Section: Discussionmentioning

confidence: 56%

“…The LA has previously demonstrated sensitivity comparable to that of the hc2 (11,14,20,28) and was used in this study to resolve discordant hc2 and c4800 results and confirm paired-positive results. Total nucleic acid was extracted from 400 l of LBC specimen and eluted into 110 l using the easyMAG extractor (bioMérieux Canada Inc., Québec, Canada).…”

Section: Methodsmentioning

confidence: 96%

“…High-risk HPV testing (when used as either primary screening or for reflex testing following a nonnegative cytology result) improves patient management by providing a more accurate risk assessment for cervical cancer or its precursors (9,11,14,20,22,24). The first HR HPV test approved by the U.S. Food and Drug Administration (FDA) was the Hybrid Capture 2 (hc2) high-risk HPV DNA test (Qiagen, Mississauga, Ontario, Canada), which detects HPV by hybridization of genotype-specific RNA probes to denatured viral DNA.…”

mentioning

confidence: 99%

See 2 more Smart Citations

Comparison of the Hybrid Capture 2 and cobas 4800 Tests for Detection of High-Risk Human Papillomavirus in Specimens Collected in PreservCyt Medium

et al. 2012

View full text Add to dashboard Cite

Clinical cervical cytology specimens (n ‫؍‬ 466) collected in PreservCyt (Hologic Inc.) were used to evaluate the agreement between Hybrid Capture 2 (hc2; Qiagen) and cobas 4800 (c4800; Roche Molecular Diagnostics) for the detection of high-risk human papillomavirus (HR HPV) genotype infections. The agreement between the two assays was 93.8% (kappa ‫؍‬ 0.87; 95% confidence interval, 0.828 to 0.918), with 186 and 251 concordant positive and negative results, respectively. All 186 concordant positives were confirmed using the Linear Array (LA; Roche Molecular Diagnostics) genotyping test. Of the 29 samples with discordant results (6.2%), 18 were hc2 positive and LA verified 17 as positive for HR HPV. Eleven discordant specimens were c4800 positive, and LA confirmed 5 as positive for HR HPV. As of October 2009, practice guidelines in Alberta, Canada, recommend reflex HPV testing for women over 30 years old with atypical squamous cells of undetermined significance (ASCUS) and for women over 50 years old with low-grade squamous intraepithelial lesions (LSIL) to help prioritize those who should undergo further evaluation. In this study, agreement between hc2 and c4800 results for samples from women over 30 years old with ASCUS cytology was 92.3% (n ‫؍‬ 13), while no samples from women over 50 years old with LSIL cytology were identified for analysis. Studies have shown that cervical cancer is a preventable disease, and its incidence and associated mortality rate have declined since the advent of Papanicolau (Pap) test screening programs (13,17). Opportunities for primary prevention and enhanced secondary prevention exist because of the understanding that human papillomaviruses (HPV) cause cervical cancer (33). To date, about 120 HPV genotypes have been classified (2); approximately 60 genotypes are known to infect the human genital tract, of which 12 genotypes (HPV 16,18,31,33, 35, 39, 45, 51, 52, 56, 58, and 59) are considered oncogenic or high risk (HR) and 5 genotypes (HPV 26, 53, 66, 68, and 72) are considered possibly oncogenic as their significance in cervical cancer incidence is unclear (21, 26). Persistent HR HPV infection is a requirement for progression from squamous intraepithelial lesions (SIL) to cervical intraepithelial neoplasia (CIN) and finally cervical cancer (7,10,16,27,30). Studies worldwide have shown that HPV 16 is detected most often (50 to 60%) in cervical cancer cases, followed by HPV 18 (10 to 12%) and HPV 31 and HPV 45 (4 to 5% each) (3). In the vast majority of women, HPV infections occur at a young age shortly after sexual debut and are transient. Detection of HR HPV in women over the age of 30 years is an indication that persistent infection may be occurring (7), which is necessary for the development of cervical cancer.Pap testing has limitations such as interoperator variability and low sensitivity. High-risk HPV testing (when used as either primary screening or for reflex testing following a nonnegative cytology result) improves patient management by providing a more accurate risk as...

show abstract

Section: Discussionmentioning

confidence: 56%

Section: Methodsmentioning

confidence: 96%

mentioning

confidence: 99%

See 1 more Smart Citation

Comparison of the Hybrid Capture 2 and cobas 4800 Tests for Detection of High-Risk Human Papillomavirus in Specimens Collected in PreservCyt Medium

et al. 2012

View full text Add to dashboard Cite

show abstract

“…HPV DNA detection and genotyping were carried out using the Linear Array (LA) HPV Genotyping Test (Roche Diagnostics). Briefly, HPV DNA was amplified by PCR using a pool of biotin-labeled primers that hybridize in the L1 region (18,23,24 (25). For the purposes of this study, undetermined-risk and LR HPV types were combined.…”

Section: Methodsmentioning

confidence: 99%

High-risk human papillomavirus E6/E7 mRNA and L1 DNA as markers of residual/recurrent cervical intraepithelial neoplasia

et al. 2012

View full text Add to dashboard Cite

Abstract. The aim of this study was to assess the use of human papillomavirus (HPV) E6/E7 mRNA testing in the follow-up of women treated for cervical intraepithelial neoplasia (CIN) by conization and to compare the prognostic value of HPV E6/E7 mRNA to HPV L1 DNA and cytology. One hundred and forty-three women underwent cytological/histological testing, HPV DNA genotyping by Linear Array, and HPV E6/ E7 mRNA testing by APTIMA HPV assay during followup after surgical treatment for histologically verified CIN. High-grade residual/recurrent disease (CIN2 + /HSIL + ) was identified in 7 (4.9%) women, and low-grade disease (CIN1/ LSIL) in 25 (17.5%). At the inclusion visit 33 (23%) women were HPV DNA-positive; 13 (9.0%) were HPV E6/E7 mRNApositive. HPV E6/E7 mRNA did not identify three women with high-grade disease. Presence of high-risk HPV DNA at the inclusion visit predicted 100% (95% CI 64.6-100) of high-grade residual/recurrent disease, with a specificity of 80.9% (95% CI 73.5-86.6); cytology had a sensitivity of 85.7%, and a specificity of 87.5%. HPV E6/E7 mRNA testing was a poor predictor of treatment failure, with a sensitivity of 57.1% (95% CI 25.0-84.2), but high specificity (93.4%; 95% CI 87.9-96.5). Detection of high-risk HPV DNA after treatment by conization identified 100% of women with residual/recurrent high-grade disease, whereas HPV E6/E7 mRNA testing was a poor predictor of treatment failure. This study suggests that a negative HPV mRNA result cannot exclude the risk of malignant progression, and that HPV E6/E7 mRNA testing by APTIMA HPV assay is not useful in the follow-up of women treated for CIN.

show abstract

“…2) with several signs of inflammatory activation in the cervical biopsy. However, the test was negative for HPV DNA at inclusion as well as at follow-up, and the sensitivity of Linear Array is very high (44,45). None of the women had a clinically overt lesion; thus, we may not have taken the biopsy at the site of infection/inflammation.…”

Section: Discussionmentioning

confidence: 99%

Slumbering mucosal immune response in the cervix of human papillomavirus DNA-positive and -negative women

Wendel

Kaldensjö²,

Peterson³

et al. 2010

Int J Oncol

View full text Add to dashboard Cite

Abstract. Persistent human papillomavirus (HPV) infection is a prerequisite for cervical cancer and results from bypassing the local immune response. Twenty-four volunteers underwent an ectocervical biopsy, Pap smear, tests for sexually transmitted infections including HIV and HPV genotyping. All answered a questionnaire regarding medical history. Repeat Pap smear and HPV genotyping was performed 9-26 months later. Quantitative reverse transcriptase (qRT-)PCR was used to assess expression of CD3, CD4, CD8, CD19, CD27, IL-2, IL-12, IL-4, IL-10, IL-17, HLA-DR·, TGFß, IFNÁ, PD-1, PD-L1, CTLA-4, LAG3, IgA, IgG, CCR5, CCL5/RANTES and the IL-7 receptor in the biopsies. Eleven of 24 volunteers were HPV DNA-positive at baseline. Four of 10 were infected with a persistent HPV genotype at followup. All target molecules were successfully amplified and quantified except for IL-4. We found no difference in mRNA expression of these molecules when comparing HPV DNApositive and -negative women, neither when comparing persistently infected individuals or those who cleared the infection. However, mRNA expression of the B cell phenotypic marker CD19 was higher in women using hormonal contraception than those not (p<0.05). HPV infection does not evoke a local inflammatory immune response in the ectocervix measurable with qRT-PCR. Hormonal contraception may influence B cell activity in the cervix.

show abstract

Detection of Human Papillomavirus Genotypes Among High-Risk Women: A Comparison of Hybrid Capture and Linear Array Tests

Abstract: Performance of HCII and LA does not significantly differ in detecting CIN2+ or CIN3+.

Cited by 26 publications

References 38 publications

Comparison of the Hybrid Capture 2 and cobas 4800 Tests for Detection of High-Risk Human Papillomavirus in Specimens Collected in PreservCyt Medium

Comparison of the Hybrid Capture 2 and cobas 4800 Tests for Detection of High-Risk Human Papillomavirus in Specimens Collected in PreservCyt Medium

High-risk human papillomavirus E6/E7 mRNA and L1 DNA as markers of residual/recurrent cervical intraepithelial neoplasia

Slumbering mucosal immune response in the cervix of human papillomavirus DNA-positive and -negative women

Contact Info

Product

Resources

About